Home / Expertise / Life Sciences & Healthcare

Life Sciences & Healthcare

Spain

CMS Albiñana & Suárez de Lezo provides advice on all aspects affecting the pharmaceutical industry, including domestic and international corporate transactions as well as regulatory, intellectual property and dispute resolution matters relating to product or other forms of liability.

We boast a team of more than 200 lawyers specialising in healthcare and pharmaceutical law with the support of the Lifesciences Asia-Pacific Network (LAN), enabling us to understand the scientific, commercial and legal obligations affecting pharmaceutical companies. We work with the 100 most important pharmaceutical, medical equipment, biotechnology, agriculture and food companies, including 20 pharmaceutical multinationals and nine of the ten biggest medical equipment enterprises.

With active members in key sector associations such as ABPI, ABPI, BIVDA, PAGB, EUCOMED and EFPIA, we contribute to the design of regulatory frameworks affecting the pharmaceutical and healthcare sectors. We advise clients on their daily operational needs, including advertising and promotion, as well as public procurement, price and refund policies, the use of patents, commercial agreements and clinical trials. Moreover, we also provide regulatory advice on complex issues relating to strategic agreements, corporate transactions and legal proceedings for product or other forms of liability.

Read more Read less

Feed

Show only
08/07/2008
CMS Life Sci­ences Mono­graph Clin­ic­al Tri­als
27 Mar 20
Man­aging clin­ic­al tri­als un­der COV­ID-19: New EU guid­ance is­sued for...
The COV­ID-19 pan­dem­ic has had a dra­mat­ic im­pact on European health sys­tems, whose pri­or­ity first and fore­most is the treat­ment of pa­tients suf­fer­ing from this dis­ease both in the in-pa­tient and out-pa­tient...
CMS Ex­pert Guide to a Leg­al Roadmap to Can­nabis
26 Mar 20
European Com­mis­sion pro­poses delay­ing the May 2020 ap­plic­a­tion of...
The European Com­mis­sion has con­firmed it is work­ing on a pro­pos­al to delay for one year the date of ap­plic­a­tion of the new EU Med­ic­al Devices Reg­u­la­tion 2017/745/EU (the “MDR”) in light of the Cov­id-19...
CMS Ex­pert Guide to Ad­vert­ising of Phar­ma­ceut­ic­als...
17 Mar 20
While doc­tors fight COV­ID-19 au­thor­it­ies battle fraud, price hikes...
In every coun­try hit by COV­ID-19, the dis­ease linked to the Coronavir­us, com­pet­i­tion and con­sumer pro­tec­tion au­thor­it­ies have been con­fron­ted with the vir­us's im­plic­a­tions. Gov­ern­ments, au­thor­it­ies and...
10 Mar 20
EU Com­mis­sion's White Pa­per on Ar­ti­fi­cial In­tel­li­gence stresses ex­cel­lence...
Ar­ti­fi­cial in­tel­li­gence (AI) has now reached al­most all areas of life: mo­bil­ity, trade and health, to name but a few. As a res­ult, the EU Com­mis­sion has sum­mar­ised its vis­ion for the fu­ture of AI and...
06 Mar 20
MDR - Agree­ments with third party con­tract man­u­fac­tur­ers
The EU Med­ic­al Device Reg­u­la­tion, which comes in­to force on 26 May 2020, will lead not only to big changes in how med­ic­al devices are reg­u­lated, but also to more thought be­ing giv­en to agree­ments between...
28 Feb 20
Pat­ent­ing Ar­ti­fi­cial In­tel­li­gence and quantum tech­no­lo­gies
IP and Life Sci­ence ana­lys­is: Caitlin Heard, IP Lit­ig­a­tion Part­ner, and Rachel Free, Pat­ent At­tor­ney and Part­ner, at CMS Camer­on McK­enna, dis­cuss the ap­plic­ab­il­ity of Ar­ti­fi­cial In­tel­li­gence (AI) and...
26 Feb 20
Can­nabis mark ruled con­trary to pub­lic policy
Back­ground On 19 Decem­ber 2016, Ms Santa Conte (“Ms Conte”) made an ap­plic­a­tion to re­gister an EU trade mark for the fol­low­ing fig­ur­at­ive sign in re­la­tion to vari­ous food and drink products and ser­vices...
31 Jan 20
UK In­tel­lec­tu­al Prop­erty Of­fice finds that pat­ent law does not cater...
The UK In­tel­lec­tu­al Prop­erty Of­fice has found that DABUS is not a per­son and so can­not be con­sidered an in­vent­or of a pat­ent. DABUS is an ar­ti­fi­cial in­tel­li­gence (AI) ma­chine. The UKIPO ac­cep­ted the in­dic­a­tion...
17 Jan 20
New guid­ance on cy­ber­se­cur­ity for med­ic­al devices pub­lished
In Decem­ber 2019, the Med­ic­al Device Co­ordin­a­tion Group (“MD­CG”) is­sued a new guid­ance to help med­ic­al device man­u­fac­tur­ers meet the cy­ber­se­cur­ity re­quire­ments in the Med­ic­al Devices Reg­u­la­tion (“MDR”)...